| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-385 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate |
2011-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2013-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2013526582-A |
| titleOfInvention |
Cancer treatment |
| abstract |
A cell-based vaccine that prolongs the survival of cancer patients. This vaccine is irradiated and cultured lung adenocarcinoma cells (AD 100) transduced with HLA A1 and gp96-Ig (human gp96 in which the endoplasmic reticulum retention signal KDEL has been replaced by the Fc-part of human IgG1). ), Advanced, relapsed, or metastatic NSCLC affected patients were injected endothelially. Vaccine administration increased the patient's average survival time compared to similar patients treated with placebo. Furthermore, the patient's immune response to the vaccine (antigen-induced production of interferon-γ by T cells) correlated with survival time. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018509888-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021505138-A |
| priorityDate |
2010-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |